United States-based pharmaceutical manufacturer AbbVie will invest $380 million (€322 million) to construct two new manufacturing facilities at its North Chicago, Illinois campus, the company announced 23 February, according to a Chicago Sun-Times report.

The plants will manufacture active pharmaceutical ingredients for AbbVie's obesity and neuroscience medications. The facilities will create at least 300 full-time positions including roles for engineers, scientists, manufacturing operators and laboratory technicians. Construction will commence this spring, with facilities opening in 2029.

"This milestone demonstrates further progress against AbbVie's $100 billion commitment to U.S. research and development, and capital investments over the next decade," said Robert Michael, chief executive officer of AbbVie.

The investment follows AbbVie breaking ground in September 2025 on a $195 million (€165 million) manufacturing facility in North Chicago, which will create approximately 50 full-time positions when operational in 2027. That plant will manufacture neuroscience, immunology and oncology products.

"AbbVie's significant investment fortifies Illinois' position as a global biomanufacturing leader while creating hundreds of new jobs," said JB Pritzker, governor of Illinois. "With our world-class workforce, modern infrastructure, strategic location and cutting-edge research ecosystem, this expansion underscores why Illinois is the best place to grow and innovate."

In January 2026, AbbVie announced a voluntary agreement with the Trump administration to invest $100 billion (€84 billion) in United States-based research and development and capital investments over the next decade. The agreement includes Trump administration exemption from tariffs and future price mandates for AbbVie.

For the two new facilities, AbbVie will receive a tax credit worth an estimated $25 million (€21 million) over 15 years through Illinois' Economic Development for a Growing Economy agreement.

View comprehensive coverage of AbbVie's manufacturing investment and expansion strategy in the full story.